Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cybin Inc. stock logo
CLXPF
Cybin
$0.36
$0.39
$0.49
$3.38
$52.75MN/A551,962 shs3.44 million shs
EMC Corp stock logo
EMC
EMC
$25.60
+0.2%
$0.00
$22.99
$29.13
N/AN/A13.90 million shs12,263 shs
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
$0.39
$0.19
$28.00
$906K2.19462,687 shs2.25 million shs
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
$1.47
-1.3%
$1.64
$1.46
$3.82
$24.68M0.8786,095 shs81,943 shs
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cybin Inc. stock logo
CLXPF
Cybin
-1.99%-2.80%-13.66%-5.48%-1.80%
EMC Corp stock logo
EMC
EMC
+1.87%+1.43%-1.58%+2.71%-12.08%
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
0.00%0.00%0.00%-59.20%-99.25%
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
+0.68%-1.97%-5.10%-13.37%-31.96%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cybin Inc. stock logo
CLXPF
Cybin
N/AN/AN/AN/AN/AN/AN/AN/A
EMC Corp stock logo
EMC
EMC
N/AN/AN/AN/AN/AN/AN/AN/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/AN/AN/AN/AN/AN/AN/AN/A
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
4.1287 of 5 stars
3.53.00.04.73.10.80.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cybin Inc. stock logo
CLXPF
Cybin
N/AN/AN/AN/A
EMC Corp stock logo
EMC
EMC
N/AN/AN/AN/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/AN/AN/AN/A
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
3.00
Buy$6.00308.16% Upside

Current Analyst Ratings

Latest NEPT, EMC, ARIX, UBX, and CLXPF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/16/2024
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$10.00 ➝ $8.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cybin Inc. stock logo
CLXPF
Cybin
$680K77.58N/AN/A$0.44 per share0.81
EMC Corp stock logo
EMC
EMC
N/AN/AN/AN/AN/AN/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
$52.62M0.00N/AN/A($91.90) per share0.00
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
$240K102.84N/AN/A$1.69 per share0.87

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cybin Inc. stock logo
CLXPF
Cybin
-$24.42M-$0.24N/AN/AN/AN/AN/AN/AN/A
EMC Corp stock logo
EMC
EMC
N/A$2.0512.49N/AN/AN/AN/AN/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%7/15/2024 (Estimated)
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
-$39.86M-$2.94N/AN/AN/AN/A-95.06%-46.86%5/14/2024 (Estimated)

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cybin Inc. stock logo
CLXPF
Cybin
N/AN/AN/AN/AN/A
EMC Corp stock logo
EMC
EMC
$0.461.80%N/A22.44%N/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/AN/AN/AN/AN/A
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cybin Inc. stock logo
CLXPF
Cybin
N/A
13.57
13.57
EMC Corp stock logo
EMC
EMC
N/AN/AN/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/A
0.23
0.10
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
N/A
5.94
5.94

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Cybin Inc. stock logo
CLXPF
Cybin
0.01%
EMC Corp stock logo
EMC
EMC
79.86%
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
14.44%
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
29.49%

Insider Ownership

CompanyInsider Ownership
Cybin Inc. stock logo
CLXPF
Cybin
N/A
EMC Corp stock logo
EMC
EMC
0.40%
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
5.10%
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
4.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Cybin Inc. stock logo
CLXPF
Cybin
6148.60 millionN/ANot Optionable
EMC Corp stock logo
EMC
EMC
N/AN/AN/ANot Optionable
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
584.53 million4.30 millionNot Optionable
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
2216.79 million15.96 millionOptionable

NEPT, EMC, ARIX, UBX, and CLXPF Headlines

SourceHeadline
UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DMEUNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME
globenewswire.com - April 23 at 8:00 AM
Equities Analysts Issue Forecasts for Unity Biotechnology, Inc.s FY2024 Earnings (NASDAQ:UBX)Equities Analysts Issue Forecasts for Unity Biotechnology, Inc.'s FY2024 Earnings (NASDAQ:UBX)
americanbankingnews.com - April 19 at 2:31 AM
Q1 2024 Earnings Forecast for Unity Biotechnology, Inc. Issued By HC Wainwright (NASDAQ:UBX)Q1 2024 Earnings Forecast for Unity Biotechnology, Inc. Issued By HC Wainwright (NASDAQ:UBX)
americanbankingnews.com - April 18 at 1:26 AM
YOUTH UNITY EVENT TO BE HELD AT BOYS AND GIRLS CLUBYOUTH UNITY EVENT TO BE HELD AT BOYS AND GIRLS CLUB
kscj.com - April 17 at 7:01 PM
Unity Biotechnology (NASDAQ:UBX) Price Target Cut to $8.00 by Analysts at HC WainwrightUnity Biotechnology (NASDAQ:UBX) Price Target Cut to $8.00 by Analysts at HC Wainwright
americanbankingnews.com - April 17 at 3:42 AM
UBX Stock Earnings: Unity Biotechnology Beats EPS for Q4 2023UBX Stock Earnings: Unity Biotechnology Beats EPS for Q4 2023
investorplace.com - April 15 at 12:06 PM
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdatesUNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
globenewswire.com - April 15 at 7:00 AM
Unity Biotechnology, Inc. (0YC0.L)Unity Biotechnology, Inc. (0YC0.L)
finance.yahoo.com - April 9 at 7:15 PM
UBX Mar 2024 2.000 callUBX Mar 2024 2.000 call
finance.yahoo.com - February 17 at 6:28 AM
Unity Biotechnology Inc (UBX)Unity Biotechnology Inc (UBX)
uk.investing.com - February 7 at 9:59 AM
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision LossNew Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss
finance.yahoo.com - February 6 at 10:46 AM
Guest column: UNITY is making strides in tackling homelessness in Tremes despite what critics sayGuest column: UNITY is making strides in tackling homelessness in Tremes despite what critics say
nola.com - February 1 at 6:40 PM
10 Supplements for Longevity and Antiaging: Expert Recommendations10 Supplements for Longevity and Antiaging: Expert Recommendations
finance.yahoo.com - December 29 at 6:53 PM
UNITY Biotechnology doses first patients in phase 2 ASPIRE study of UBX1325UNITY Biotechnology doses first patients in phase 2 ASPIRE study of UBX1325
pharmabiz.com - December 14 at 2:33 AM
UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DMEUNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME
finance.yahoo.com - December 12 at 8:12 AM
Unity Biotechnology (UBX) Price Target Increased by 8.33% to 6.63Unity Biotechnology (UBX) Price Target Increased by 8.33% to 6.63
msn.com - November 27 at 7:50 AM
Wedbush Upgrades Unity Biotechnology (UBX)Wedbush Upgrades Unity Biotechnology (UBX)
msn.com - November 17 at 6:09 AM
Wedbush upgrades Unity Biotechnology to outperform, cites cash runwayWedbush upgrades Unity Biotechnology to outperform, cites cash runway
msn.com - November 16 at 4:06 PM
Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite RiskyCompanies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky
finance.yahoo.com - November 16 at 11:05 AM
Unity Biotechnology’s Promising Senolytic Therapy UBX1325 and Financial Stability Bolsters Buy RatingUnity Biotechnology’s Promising Senolytic Therapy UBX1325 and Financial Stability Bolsters Buy Rating
markets.businessinsider.com - November 15 at 11:51 AM
Unity Biotechnology, Inc.: UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business UpdatesUnity Biotechnology, Inc.: UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates
finanznachrichten.de - November 14 at 10:45 PM
Unity Biotechnology GAAP EPS of -$1.05 misses by $0.16Unity Biotechnology GAAP EPS of -$1.05 misses by $0.16
msn.com - November 14 at 2:01 AM
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business UpdatesUNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates
tmcnet.com - November 13 at 9:00 PM
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business UpdatesUNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates
finance.yahoo.com - November 13 at 9:00 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Cybin logo

Cybin

OTCMKTS:CLXPF
Cybin Inc., a life sciences company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Natures Journey. The Serenity Life segment engages in the research and development of pharmaceutical and nutraceutical psilocybin products. The Natures Journey segment focuses on non-psychedelic medical mushroom nutraceutical products. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.
EMC logo

EMC

NYSE:EMC
EMC Corporation (EMC) develops, delivers and supports the information technology (IT) industry's range of information infrastructure and virtual infrastructure technologies, solutions and services. EMC manages the Company as part of a federation of businesses: EMC Information Infrastructure, VMware Virtual Infrastructure, Pivotal and Virtustream. EMC's Information Infrastructure business provides a foundation for organizations to store, manage, protect, analyze and secure information. EMC's VMware Virtual Infrastructure business is engaged in virtualization and cloud infrastructure solutions that enable businesses to help transform the way they build, deliver and consume IT resources in a manner that is based on their specific needs. EMC's Pivotal business unites strategic technology, people and programs from EMC and VMware and has a platform that consists of data, agile development practices and a cloud independent platform-as-a-service.
Neptune Wellness Solutions logo

Neptune Wellness Solutions

NASDAQ:NEPT
Neptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada.
Unity Biotechnology logo

Unity Biotechnology

NASDAQ:UBX
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.